A naukri.com initiative
Bioengineer
1w
256
Image Credit: Bioengineer
Pan-Cancer Study Reveals DNA Repair Defects
- A pan-cancer study in a large Asian cohort sheds light on homologous recombination deficiency (HRD) and homologous recombination repair (HRR) gene alterations in various solid tumors.
- HRD plays a crucial role in determining sensitivity to certain chemotherapies and PARP inhibitors, with the study expanding this understanding beyond BRCA-associated cancers.
- Researchers used advanced genomic sequencing techniques to assess HRD scores and biallelic loss in key HRR genes, aiding in stratifying tumors based on DNA repair proficiency.
- Significant variation in HRD scores was observed across different cancer types, with distinct patterns reflecting genomic instability and alterations in HRR genes beyond BRCA mutations.
- Biallelic loss of genes like BRCA1, BRCA2, and others was linked to heightened genomic instability, indicating diverse HRR pathway disruptions in different tumor types.
- TP53 alterations further elevated HRD levels, suggesting a synergistic relationship impacting tumor susceptibility profiles irrespective of HRR gene changes.
- Clinical correlations revealed higher HRD scores in advanced-stage tumors with specific characteristics, highlighting associations with aggressive disease and immune evasion.
- The study addresses the importance of inclusive genomic studies and advocates for refined diagnostic approaches integrating multi-gene panels for personalized cancer therapies.
- Findings on cancer-specific HRD signatures at the chromosomal level open avenues for biomarker development, enhancing personalized medicine beyond traditional approaches.
- The research marks a milestone in understanding DNA repair deficiencies across solid tumors, emphasizing the potential of HRD as a universal biomarker for targeted therapies.
Read Full Article
15 Likes
For uninterrupted reading, download the app